title: Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
abstract: OBJECTIVE
  Antiproliferative and antiosteoclastic activity from preclinical models show potential for dasatinib, an oral SRC and SRC family kinase inhibitor, as a targeted therapy for patients with prostate cancer. This phase II study investigated the activity of dasatinib in patients with metastatic castration-resistant prostate cancer (CRPC).
  
  
  METHODS
  Chemotherapy-naive men with CRPC and increasing prostate-specific antigen were treated with dasatinib 100 or 70 mg twice daily. Endpoints included changes in prostate-specific antigen, bone scans, measurable disease (Response Evaluation Criteria in Solid Tumor), and markers of bone metabolism. Following Prostate Cancer Working Group 2 guidelines, lack of progression according to Response Evaluation Criteria in Solid Tumor and bone scan was determined and reported at 12 and 24 weeks.
  
  
  RESULTS
  Forty-seven patients were enrolled and received dasatinib (initial dose 100 mg twice daily, n = 25; 70 mg twice daily, n = 22), of whom 41 (87%) had bone disease. Lack of progression was achieved in 20 (43%) patients at week 12 and in 9 (19%) patients at week 24. Of 41 evaluable patients, 21 (51%) patients achieved > or =40% reduction in urinary N-telopeptide by week 12, with 33 (80%) achieving some level of reduction anytime on study. Of 15 patients with elevated urinary N-telopeptide at baseline, 8 (53%) normalized on study. Of 40 evaluable patients, 24 (60%) had reduction in bone alkaline phosphatase at week 12 and 25 (63%) achieved some reduction on study. Dasatinib was generally well tolerated and treatment-related adverse events were moderate.
  
  
  CONCLUSIONS
  This study provides encouraging evidence of dasatinib activity in bone and reasonable tolerability in chemotherapy-naive patients with metastatic CRPC.
authors.affiliation: University of Washington, Seattle, Washington, USA.
authors.forename: Evan Y
authors.initials: EY
authors.lastname: Yu
authors.forename: George
authors.initials: G
authors.lastname: Wilding
authors.forename: Edwin
authors.initials: E
authors.lastname: Posadas
authors.forename: Mitchell
authors.initials: M
authors.lastname: Gross
authors.forename: Stephane
authors.initials: S
authors.lastname: Culine
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Morris
authors.forename: Gary
authors.initials: G
authors.lastname: Hudes
authors.forename: Fabio
authors.initials: F
authors.lastname: Calabrò
authors.forename: Shinta
authors.initials: S
authors.lastname: Cheng
authors.forename: Géralyn C
authors.initials: GC
authors.lastname: Trudel
authors.forename: Prashni
authors.initials: P
authors.lastname: Paliwal
authors.forename: Cora N
authors.initials: CN
authors.lastname: Sternberg
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D049109:Cell Proliferation; D000069439:Dasatinib; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000096:biosynthesis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D017430:Prostate-Specific Antigen; D000069439:Dasatinib